arrow
J

Jared D. Acoba

university of southern california keck hospital
H指数:20
被引数:3,813

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival disparities in non-small cell lung cancer: Disaggregating Asians from NHPI and identifying variability among common Asian subgroups - The largest single-center study in Hawai'i

非小细胞肺癌的生存差异:将亚洲人与太平洋岛屿原住民及阿拉斯加原住民区分开,并识别常见亚洲亚群中的变异性——夏威夷最大单中心研究

2025-12-010
PRE
Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

卡博赞替尼 versus 安慰剂用于既往治疗后进展的晚期神经内分泌肿瘤(NET)(CABINET 试验/Alliance A021602):更新结果包括根据盲态独立中心审查(BICR)的无进展生存期(PFS)及亚组分析

2024-09-010
PRE
American Society for Gastrointestinal Endoscopy guideline on role of endoscopy in the diagnosis of malignancy in biliary strictures of undetermined etiology: methodology and review of evidence
2023-11-018
PRE
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

乳腺癌和新型冠状病毒肺炎患者的临床特征,种族不平等和结局: 新型冠状病毒肺炎和癌症联盟 (CCC19) 队列研究

2023-10-172
OA
Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

联盟A021602: 卡博替尼与安慰剂治疗晚期神经内分泌肿瘤 (NET) 的III期双盲研究 (内阁)

2023-10-0118
PRE
A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores
2021-06-157
PREAI
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

癌症患者的临床因素和近期抗癌治疗与新型冠状病毒肺炎严重程度的关系: 新型冠状病毒肺炎和癌症协会的报告

2021-06-01237
OAAI
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds
2009-03-1755
OAAI